Market research
ATHX Athersys Inc
PINK USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 833K
- P/E ratio
- Not available
- Analyst target
- 5.5
- Dividend yield
- Not available
- Beta
- -0.9
Profile
Company facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US04744L2051
- Market cap
- 833K
- P/E ratio
- Not available
- Analyst target
- 5.5
- Dividend yield
- Not available
- Beta
- -0.9
About
About Athersys Inc
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On January 5, 2024, Athersys, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Ohio.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ATHX discussion.
5 years, 4 months ago
Athersys, Inc is currently in a long term downtrend where the price is trading 21.3% below its 200 day moving average.
From a valuation standpoint, the stock is 81.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 252.6.
Athersys, Inc's total revenue sank by 99.5% to $1K since the same quarter in the previous year.
Its net income has increased by 100.2% to $16K since the same quarter in the previous year.
Finally, its free cash flow fell by 74.9% to $-18M since the same quarter in the previous year.
Based on the above factors, Athersys, Inc gets an overall score of 2/5.